These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10199461)

  • 21. Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer.
    Razis E; Kosmidis P; Aravantinos G; Bakoyiannis C; Janinis J; Timotheadou H; Christodoulou C; Fountzilas G
    Cancer Invest; 2004; 22(1):10-5. PubMed ID: 15069759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
    Kouroussis C; Kalbakis K; Androulakis N; Agelaki S; Vamvakas L; Malas K; Souglakos J; Vardakis N; Georgoulias V
    Anticancer Res; 2004; 24(6):4217-21. PubMed ID: 15736475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.
    Hochster HS; Vogel CL; Burman SL; White R
    Oncologist; 2001; 6(3):269-77. PubMed ID: 11423674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study.
    Llombart-Cussac A; Pivot X; Rhor-Alvarado A; Le Cesne A; Le Chevalier T; Tursz T; Spielmann M
    Oncology; 1998; 55(5):384-90. PubMed ID: 9732214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.
    Dieras V; Extra JM; Bellissant E; Espie M; Morvan F; Pierga JY; Mignot L; Tresca P; Marty M
    J Clin Oncol; 1996 Dec; 14(12):3097-104. PubMed ID: 8955654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.
    Chang AY; Garrow GC
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):66-70; discussion 70-1. PubMed ID: 7740336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer.
    Shamseddine AI; Taher A; Dabaja B; Dandashi A; Salem Z; El Saghir NS
    Am J Clin Oncol; 1999 Jun; 22(3):298-302. PubMed ID: 10362341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel.
    Zambetti M; Mariani G; Demicheli R; Verderio P; Potepan P; Garbagnati F
    Breast Cancer Res Treat; 2000 Jul; 62(2):135-9. PubMed ID: 11016751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M
    Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
    Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
    Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
    Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
    Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
    Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
    Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
    Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.